The 2012 Health and Social Care Act was the largest ever reorganisation of the English NHS.1 It attracted […]

The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)

Concerns over NHS Test and Trace system exacerbated by continuing rise in cases

Tumour agnostic therapy demonstrates sustained efficacy

The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC

For the first time, scientists solved the high-resolution structure of these compounds when they are actively bound to […]

Updated Date: Thu, 10 Sep 2020 00:00:00 EDT

Updated Date: Thu, 10 Sep 2020 00:00:00 EDT

Updated Date: Thu, 10 Sep 2020 00:00:00 EDT

Updated Date: Thu, 10 Sep 2020 00:00:00 EDT